Downgrading of regulation in regenerative medicine-Reference-Cited by-同舟云学术

Downgrading of regulation in regenerative medicine

Published:2019-08-16 Issue:6454 Volume:365 Page:644-646
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Sipp Douglas¹²³⁴,Sleeboom-Faulkner Margaret⁵

Affiliation:

1. RIKEN Center for Biosystems Dynamics, Kobe, Japan.

2. Keio University School of Medicine, Tokyo, Japan.

3. Keio University Global Research Institute, Tokyo, Japan.

4. RIKEN Advanced Intelligence Project, Tokyo, Japan.

5. Department of Anthropology, School of Global Studies, University of Sussex, Brighton, UK.

Abstract

What should be a firm commitment to product efficacy is threatened by economic competition

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference8 articles.

1. Regulatory brokerage: Competitive advantage and regulation in the field of regenerative medicine

2. ‘Reprogrammed’ stem cells approved to mend human hearts for the first time

3. K. Kurata Y.-H. Choi “Dissemination of Regenerative Medicine in Japan: Promoting commercialization under the regulatory system.” Research Institute of Economy Trade and Industry January 2012; www.rieti.go.jp/jp/publications/dp/12e004.pdf.

4. Japan’s approval of stem-cell treatment for spinal-cord injury concerns scientists

5. Introduction of new therapeutic drugs in the United States and Great Britain: An international comparison

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polish regulatory system regarding ATMP hospital exemptions;Frontiers in Immunology;2024-05-13

2. US state laws on medical freedom and investigational stem cell procedures: a call to focus on state-based legislation;Cytotherapy;2024-04

3. International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products;Cytotherapy;2023-09

4. The evolving regulatory landscape in regenerative medicine;Molecular Aspects of Medicine;2023-06

5. Responsible innovation in stem cell research: using responsibility as a strategy;Regenerative Medicine;2023-03